A new study found proposed Medicare drug pricing models may rely on prices from relatively few international markets.
Pharma
Case examines allegations involving AstraZeneca under the ABPI Code, underscoring the compliance controls drugmakers need to implement.
Analysing the compliance imperatives for both US pharma and the strategic considerations for Chinese biotech navigating the cross-border environment.
Justices rule drugmakers cannot be liable for delaying safer alternatives when existing products are FDA approved and nondefective.
The US Food and Drug Administration is consolidating key functions, updating reporting structures, and formalizing realignment to improve coordination.
The group urges Canadian government to address affordability, regulatory modernization, and supply-chain resilience.
Our in-brief roundup of notable healthcare and life sciences stories from the last two weeks.
The federal drug discount site has expanded its catalog and delivered steep price cuts for select medications, but is it living up to its promises.